Log in to your Inderes Free account to see all free content on this page.
Bio Vitos Pharma
0.29 SEK -0.68%Be the first to follow this company
Bio Vitos Pharma operates in the medical technology industry. The company develops and commercializes products for the detection of hemolysis in blood samples. The company has developed products that ensure that the hemolysis is detected at an early stage, which means that the blood sample can be taken care of immediately. The company also develops digital reading that is used as a complement to the main product. Bio Vitos Pharma was founded in 2010 and is headquartered in Karlstad.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
BIOVIT
Daily low / high price
0.29 / 0.292
SEK
Market cap
85.27M SEK
Turnover
86.37K SEK
Volume
296K
Financial calendar
Interim report
30.08.2024
Interim report
15.11.2024
Annual report
14.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Statevolt Group AB | 22.6 % | 22.6 % |
Bio Vitos Norge AS | 14.1 % | 14.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Bio Vitos Pharma AB: The European Patent Office EPO grants patent that is important to Bio Vitos Pharma
Hemcheck completes the transaction with Bio Vitos
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio